metricas
covid
Medicina Clínica (English Edition) Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A ...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers
Kits comercializados para evaluar la respuesta celular T frente a péptidos S del SARS-CoV-2. Un estudio piloto en trabajadores sanitarios
Mónica Martínez-Galloa,b,c,1, Juliana Esperalbad,1, Ricardo Pujol-Borrella,b,c, Víctor Sandáa, Iria Arrese-Muñoza, Candela Fernández-Navale,f, Andrés Antónd, Victoria Cardonag,h,i, Moisés Labrador-Horrillof,g,h,i,
Corresponding author
mlabrador@vhebron.net

Corresponding author.
, Tomás Pumarolad, Manuel Hernandéz-Gonzáleza,b,c
a Immunology Division, Hospital Universitari Vall d’Hebron (HUVH), Jeffrey Model Foundation Excellence Center, Barcelona, Catalonia, Spain
b Diagnostic Immunology research group Vall d’Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain
c Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain
d Microbiology Division, Hospital Universitari Vall d’Hebron (HUVH), Departament de Genètica i Microbiologia, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain
e Microbiology Department, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain
f Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
g Allergy Section, Internal Medicine Department, Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Catalonia, Spain
h ARADyAL Research Network, Instituto de Salud Carlos III (ISCIII), Spain
i Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Ver más
Read
110
Times
was read the article
0
Total PDF
110
Total HTML
Share statistics
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 10 14 0 14
2025 9 8 0 8
2025 8 7 0 7
2025 7 11 0 11
2025 6 14 0 14
2025 5 6 0 6
2025 4 2 0 2
2025 3 3 0 3
2025 2 4 0 4
2025 1 9 0 9
2024 12 2 0 2
2024 11 1 0 1
2024 10 4 0 4
2024 9 1 0 1
2024 8 2 0 2
2024 7 4 0 4
2024 6 3 0 3
2024 5 4 0 4
2024 4 3 0 3
2024 3 3 0 3
2024 2 1 0 1
2024 1 3 0 3
2023 12 1 0 1
Show all

Follow this link to access the full text of the article